Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
  • Patent number: 11987609
    Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: May 21, 2024
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shilong Fu
  • Patent number: 11981737
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: May 14, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Meher Majety, Stefan Dengl, Georg Tiefenthaler, Stefan Klostermann, Claudia Kirstenpfad, Esther Koenigsberger, Francesca Ros
  • Patent number: 11975070
    Abstract: The present invention pertains to affinity chromatography isolation and purification of extracellular vesicles (EVs). The EVs of the present invention are engineered to enable highly specific binding to e.g. chromatography matrices, which is highly useful for affinity-based isolation and purification of EVs from complex biological fluids such as cell culture medium or biological fluids.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 7, 2024
    Assignee: Evox Therapeutics Ltd
    Inventors: Oscar Wiklander, Andre Gorgens
  • Patent number: 11964005
    Abstract: The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: April 23, 2024
    Assignee: Receptos, LLC
    Inventors: Sarah Harris, Erin Babcock, Cristian Rodriguez
  • Patent number: 11958894
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: April 16, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn M. Lawrence, Amy S. Johnson, Meghan Casey, Jaimie Grapel
  • Patent number: 11953503
    Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 9, 2024
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Thorsten Keller
  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Patent number: 11952424
    Abstract: The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence. The invention also relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein at least one additional binding domain comprises a CH1 region and is connected to the base antibody portion by said linker, linking a variable region of the base antibody portion and the CH1 region, and wherein the multivalent antibody binds to at least three different epitopes.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 9, 2024
    Assignee: merus n.v.
    Inventors: Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
  • Patent number: 11945876
    Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 2, 2024
    Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
  • Patent number: 11945880
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: April 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 11939392
    Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 26, 2024
    Assignee: Aptevo Research and Development LLC
    Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
  • Patent number: 11939372
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: March 26, 2024
    Assignee: AMGEN INC.
    Inventor: Christopher J. Paszty
  • Patent number: 11912750
    Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 27, 2024
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Patent number: 11905313
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 20, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.
    Inventor: Surender Khurana
  • Patent number: 11904004
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 20, 2024
    Assignees: INSERM, UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CNRS, UNIVERSITE DE NANTES
    Inventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
  • Patent number: 11891440
    Abstract: The present invention provides for recombinant antibodies having the features of ruminant early colostrum antibodies that impart resistance to proteases and intestinal digestion. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel recombinant antibodies of the present invention, advantageously exhibit resistance to proteases and intestinal digestion. Thus, pharmaceutical compositions of the recombinant antibodies of the invention may be used to deliver antibody therapeutics particularly by oral delivery to the gastrointestinal tract when oral delivery is advantageous.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 6, 2024
    Assignee: CIRCLE33 LLC
    Inventor: Randall Edward Burton
  • Patent number: 11884739
    Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Ming-Hung Tsai
  • Patent number: 11866505
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 9, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
    Inventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
  • Patent number: 11857625
    Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 2, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sandrine Durran, Andrew Jeffrey Yates
  • Patent number: 11859011
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 11851502
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 26, 2023
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 11845793
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 19, 2023
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
  • Patent number: 11840577
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 12, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Meike Hutt, Felix Unverdorben, Sebastian Bunk, Dominik Maurer, Martin Hofmann, Gabriele Pszolla, Sara Yousef, Claudia Wagner, Frank Schwoebel, Heiko Schuster
  • Patent number: 11834716
    Abstract: Disclosed is a method for predicting whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody. Specifically, the method predicts by measurement of expression at the RNA level, or at the protein level, of at least one biomarker selected from SDC2, PTGES, NCF2, NOXA1, CARD6 and GNAZ in a tumor sample.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: December 5, 2023
    Assignee: Canbridge Life Sciences LTD
    Inventors: James Qun Xue, Jing Wang, Ya Gao, Huaizhong Hu
  • Patent number: 11834512
    Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 5, 2023
    Assignee: The Regents of the University of California
    Inventor: Arjun Deb
  • Patent number: 11827720
    Abstract: The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 28, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
  • Patent number: 11827672
    Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 28, 2023
    Assignee: Eureka Therapeutics, Inc.
    Inventors: Jun Cui, Pengbo Zhang, Yiyang Xu, Shan Li, Yixiang Xu, Guangyan Xiong, Hongruo Yun, Lianxing Liu, Xiaomei Ge, Shaohua Xu, Hong Liu, Javier Morales
  • Patent number: 11827697
    Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: November 28, 2023
    Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.
    Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
  • Patent number: 11827713
    Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: November 28, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Xiaohu Fan, Qiuchuan Zhuang, Lei Yang, Pingyan Wang, Qingyan Li
  • Patent number: 11827671
    Abstract: The invention provides methods for treating Systemic Sclerosis by administering a dual-V region bispecific antibody that specifically binds IL-4 and IL-13.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 28, 2023
    Assignee: SANOFI
    Inventors: Christina Soubrane, Corinne Esperet, Frederic Marrache, Peter Wung
  • Patent number: 11820830
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Patent number: 11813307
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: November 14, 2023
    Assignees: MERCK PATENT GMBH, ABLYNX NV
    Inventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
  • Patent number: 11795221
    Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 24, 2023
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Yong Zheng, Qiong Wu, Jing Li
  • Patent number: 11786529
    Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: October 17, 2023
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
  • Patent number: 11787868
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: October 17, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Patent number: 11773179
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 3, 2023
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Patent number: 11773175
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: October 3, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Patent number: 11718678
    Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 8, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
  • Patent number: 11707056
    Abstract: The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: July 25, 2023
    Assignee: Kymab Limited
    Inventors: Allan Bradley, E-Chiang Lee
  • Patent number: 11702473
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: July 18, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 11697690
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: July 11, 2023
    Assignee: GENZYME CORPORATION
    Inventors: Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
  • Patent number: 11685776
    Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: June 27, 2023
    Assignee: Novartis AG
    Inventors: Regis Cebe, Sebastien Irigaray, Darko Skegro
  • Patent number: 11673972
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: June 13, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 11661460
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 30, 2023
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • Patent number: 11661438
    Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 30, 2023
    Assignee: Pfizer, Inc.
    Inventors: Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
  • Patent number: 11649295
    Abstract: The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: May 16, 2023
    Assignee: argenx BV
    Inventors: Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
  • Patent number: 11643463
    Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: May 9, 2023
    Assignee: WUXI Biologics (Shanghai) Co., Ltd.
    Inventors: Zhuozhi Wang, Jing Li, Gennady Gololobov, Jianqing Xu
  • Patent number: 11643461
    Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 9, 2023
    Assignee: Forty Seven, Inc.
    Inventors: Marie Châlons-Cottavoz, Mehdi Lahmar, Klaus Schwamborn, Nicola Beltraminelli, Stéphanie Fallot, Pierre Garrone
  • Patent number: 11634506
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: April 25, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais